The sequence of the first five N-terminal amino acids was determined and was found to be Met-Glu-Lys-Ala-Met.
The activity is determined by its ability to induce osteoclast formation in RAW264.7 cells using a conc. of 5.0-10.0 ng/ml corresponding to a specific activity of 100,000-200,000 Units/mg and by dose dependant stimulation of IL-8 production in human PBMC.
The protein was lyophilized from a concentrated (1mg/ml) solution containing 10mM Tris, pH-7.5.
Sterile Filtered White lyophilized (freeze-dried) powder.
Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
It is recommended to reconstitute the lyophilized sRANKL in sterile 18MΩ-cm H2O at a concentration of 100ug/ml, which can then be further diluted to other aqueous solutions.
Lyophilized TNFSF11 although stable at room temperature for 3 weeks, should be stored desiccated below -18oC. Upon reconstitution sRANKL should be stored at 4oC between 2-7 days and for future use below -18oC.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.
Soluble Receptor Activator of NFkB Ligand, TNFSF11, TRANCE, TNF-related activation-induced cytokine, OPGL, ODF, Osteoclast differentiation factor, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa B ligand, RANKL, Osteoprotegerin ligand, CD254 antigen, sRANKL, sOdf, hRANKL2.
